title: A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis.
abstract: Corticosteroids are effective in bringing about a clinical remission in patients with ulcerative colitis. However, in severely relapsed cases, corticosteroids are not always effective even when a high dosage is administered. In addition, the long-term use of corticosteroids often causes serious side effects. Therefore, an alternative treatment for active ulcerative colitis is necessary in order to avoid these clinical problems. In the present pilot study, the efficacy of leukocytapheresis using a centrifugal procedure was evaluated for corticosteroid-resistant, active ulcerative colitis. Fourteen patients with corticosteroid-resistant severely active ulcerative colitis were treated by leukocytapheresis. Thirteen patients (92.9%) achieved clinical remission within 4 weeks after the apheresis, and remained in remission for 8 months on average without any additional corticosteroid therapy. In the remaining patient, in whom remission was not induced, a total colectomy was performed immediately after the fourth course of leukocytapheresis. No significant side effects were noticed throughout the therapy. Both colonoscopic and histological examinations confirmed the beneficial effect of this procedure in terms of the reduction of severe inflammation of the affected colon. We found that the expression of two adhesion molecules, L-selectin and VLA4a, on the surface of peripheral leukocytes was decreased after this new therapy.
authors.affiliation: Third Department of Internal Medicine, Asahikawa Medical College.
authors.forename: T
authors.initials: T
authors.lastname: Ayabe
authors.forename: T
authors.initials: T
authors.lastname: Ashida
authors.forename: M
authors.initials: M
authors.lastname: Taniguchi
authors.forename: M
authors.initials: M
authors.lastname: Nomura
authors.forename: K
authors.initials: K
authors.lastname: Einami
authors.forename: M
authors.initials: M
authors.lastname: Taruishi
authors.forename: Y
authors.initials: Y
authors.lastname: Saitoh
authors.forename: S B
authors.initials: SB
authors.lastname: Santos
authors.forename: M
authors.initials: M
authors.lastname: Ono
authors.forename: Y
authors.initials: Y
authors.lastname: Shibata
authors.forename: Y
authors.initials: Y
authors.lastname: Kohgo
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D002648:Child; D003093:Colitis, Ulcerative / Q000097:blood / Q000188:drug therapy* / Q000628:therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D039041:Integrin alpha4beta1; D016023:Integrins / Q000097:blood; D019041:L-Selectin / Q000097:blood; D007937:Leukapheresis / Q000379:methods*; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011239:Prednisolone / Q000627:therapeutic use; D016201:Receptors, Lymphocyte Homing / Q000097:blood
chemical_list: D000305:Adrenal Cortex Hormones; D039041:Integrin alpha4beta1; D016023:Integrins; D016201:Receptors, Lymphocyte Homing; D019041:L-Selectin; D011239:Prednisolone